AU2486192A - Method for lowering blood lipid levels - Google Patents

Method for lowering blood lipid levels

Info

Publication number
AU2486192A
AU2486192A AU24861/92A AU2486192A AU2486192A AU 2486192 A AU2486192 A AU 2486192A AU 24861/92 A AU24861/92 A AU 24861/92A AU 2486192 A AU2486192 A AU 2486192A AU 2486192 A AU2486192 A AU 2486192A
Authority
AU
Australia
Prior art keywords
lipid
mimetic
pro
drug
amp mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24861/92A
Other languages
English (en)
Inventor
Harry E. Gruber
Georges H. VAN DEN BERGHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of AU2486192A publication Critical patent/AU2486192A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU24861/92A 1991-08-23 1992-08-14 Method for lowering blood lipid levels Abandoned AU2486192A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74894491A 1991-08-23 1991-08-23
US748944 1991-08-23
US92975292A 1992-08-12 1992-08-12
US929752 1992-08-12

Publications (1)

Publication Number Publication Date
AU2486192A true AU2486192A (en) 1993-03-16

Family

ID=27115023

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24861/92A Abandoned AU2486192A (en) 1991-08-23 1992-08-14 Method for lowering blood lipid levels

Country Status (7)

Country Link
EP (1) EP0599987A4 (fr)
AU (1) AU2486192A (fr)
CA (1) CA2115675A1 (fr)
IL (1) IL102895A0 (fr)
MX (1) MX9204880A (fr)
NO (1) NO940580L (fr)
WO (1) WO1993003734A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492564A2 (fr) * 2001-10-31 2005-01-05 Université Libre de Bruxelles Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
ES2192495B1 (es) 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
DK3050567T3 (da) * 2013-09-26 2021-02-08 Energenesis Biomedical Co Ltd Forbindelse til aktivering af ampk og anvendelser deraf
CA3107170A1 (fr) 2018-08-06 2020-03-12 Skylark Bioscience Llc Composes activant la proteine kinase activee par l'amp et leurs utilisations
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2026040C3 (de) * 1970-05-27 1975-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Imidazolribosylcyclophosphate
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells

Also Published As

Publication number Publication date
WO1993003734A1 (fr) 1993-03-04
NO940580D0 (no) 1994-02-21
CA2115675A1 (fr) 1993-03-04
EP0599987A4 (fr) 1995-02-01
IL102895A0 (en) 1993-01-31
EP0599987A1 (fr) 1994-06-08
NO940580L (no) 1994-04-25
MX9204880A (es) 1993-04-01

Similar Documents

Publication Publication Date Title
Steinberg et al. AMP-activated protein kinase: the current landscape for drug development
Krymskaya et al. Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation
Gomez-Munoz et al. Cell-permeable ceramides inhibit the stimulation of DNA synthesis and phospholipase D activity by phosphatidate and lysophosphatidate in rat fibroblasts.
Öhrvall et al. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non—Insulin-dependent diabetes mellitus and hyperlipoproteinemia
Weishaar et al. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.
Zhou et al. Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes
Mulhall et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy
Ferrara et al. Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism
Dekkers et al. Distinct PKA and Epac compartmentalization in airway function and plasticity
Sajan et al. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C–ι
US20050209243A1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
CN112870187A (zh) 贝壳杉烷类化合物在制备人体组织中磷酸二酯酶活性的调节剂的药物应用
Wu et al. KMUP‐1, a xanthine derivative, induces relaxation of guinea‐pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels
AU2486192A (en) Method for lowering blood lipid levels
Gibbons et al. Regulation of cholesterol synthesis in the liver and mammary gland of the lactating rat
CA1119956A (fr) Procede et compose pour abaisser la tension arterielle chez les animaux
Kurata et al. Structural evaluation of glucose analogues on feeding elicitation in rat
Cui et al. The role of AMPK in macrophage metabolism, function and polarisation
US6191169B1 (en) Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
Morand et al. Importance of the modulation of glycolysis in the control of lactate metabolism by fatty acids in isolated hepatocytes from fed rats
Kane et al. Treatment of hypercholesterolemia
Bergström et al. Effect of Prostaglandin E1 on Plasma Free Fatty Acids and Blood Glucose in the Dog Prostaglandin and related factors 51
WO2001093873A1 (fr) Utilisation de aicar et de composes associes
JPH07500093A (ja) 脂質血中レベルを減少させる方法
Katz Metabolism of lipids